Trial Profile
A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms SPECTRUM
- Sponsors Amgen
- 06 Mar 2014 According to ClinicalTrials.gov, status changed from active, no longer recruiting to completed.
- 05 Jun 2013 Results published in Lancet Oncology.
- 23 Sep 2011 Results will be presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology, according to an Amgen media release.